CDC releases guidance on use of RSV vaccines in older adults

For both FDA-approved RSV vaccines, vaccination with a dose demonstrated moderate to high efficacy in preventing symptomatic RSV-associated lower respiratory tract disease among adults ages ≥60 years. On June 21, 2023, ACIP recommended that individuals ≥60 years of age may receive a single dose of RSV vaccine, using shared clinical decision-making. Tap for more details.